A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed
A phase 1/2 trial of Mezigdomide, Tazemetostat, Trametinib in multiple myeloma, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05372354 by Bristol-Myers Squibb, with 260 participants planned, started 2022-10-18 and due to reach its primary completion in 2026-10-12. Interventions recorded: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe
Shares Mezigdomide, Dexamethasone, Multiple myeloma.
- TrialOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants
Shares Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TechnologyCereblon E3 ligase modulators (CELMoDs)
Shares Mezigdomide, Multiple myeloma.
- TrialSafety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Shares Dexamethasone, Multiple myeloma.